Lantern Pharma Inc. LTRN

developments include Lantern Pharma (NASDAQ: LTRN) and TTC Oncology, who recently announced a collaborative effort to expedite the development and expansion of TTC-352, a Phase 2 trial lead drug aimed at treating metastatic ER+ breast cancer, using Lantern’s AI platform. These RADR advancements will focus on additional innovative AI and ML approaches to develop Antibody Drug Conjugates (ADC), which are highly specific cancer-targeted antibodies.

Some firms are also finding regulatory success with the FDA approving the use of an AI algorithm developed by Insilico Medicine to identify potential drug candidates for the treatment of fibrosis. Insilico Medicine’s algorithm was able to identify potential drug candidates in just 46 days, compared to the several years it typically takes to develop new drugs.

While there are only limited clinical examples of AI-developed drugs, the use of AI in preclinical and small-molecule drug development is increasing. According to a 2022 report by Nature, 25 companies are currently using AI to develop small-molecule drugs, with 11 of them having successfully advanced these drugs to a clinical stage.